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Abstract Cytochrome P450 2A6 is an important human hepatic
P450 which activates pre-carcinogens, oxidises some drugs and
constitutes the major nicotine C-oxidase. In fact, results have
been presented in the literature which suggested a relationship
between the distribution of defective CYP2A6 alleles and
smoking behaviour as well as cigarette consumption. In the
present report, we describe the structure of a novel CYP2A locus
where the whole CYP2A6 gene has been deleted, resulting in an
abolished cytochrome P450 2A6-dependent metabolism. The
origin of this locus is apparently due to an unequal crossover
event between the 3P-flanking region of the CYP2A6 and
CYP2A7 genes. A rapid PCR-based method for the detection
of the CYP2A6del allele was developed and the allele frequency
was 15.1% among 96 Chinese subjects, but only 1.0% in Finns
(n = 100) and 0.5% in Spaniards (n = 100). In the Chinese
population, we did not detect any CYP2A6*2 alleles using an
improved genotyping procedure, in contrast to the 11^20%
previously reported. It is concluded that genotyping for the
CYP2A6del allele is of great importance in studies correlating,
for example, smoking behaviour, pre-carcinogen activation or
drug metabolism to the CYP2A6 genotype, in particular when
oriental populations are investigated.
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1. Introduction
Cytochrome P450 2A6 (CYP2A6) is an important hepatic
P450 that can activate many di¡erent pre-carcinogens, includ-
ing N-nitrosodiethylamine, a£atoxin B1, 4-(methylnitrosami-
no)-1-(3-pyridyl)-1-butanone, 1,3-butadiene and 2,6-dichloro-
benzonitrile (see [1,2] and references therein). In addition,
CYP2A6 is involved in the metabolism of some pharmaceut-
icals such as methoxy£urane, halothane, (+)-cis-3,5-dimethyl-
2-(3-pyridyl) thiozolidin-4-one hydrochloride (SM-12502), lo-
sigamone, letrozole, valproic acid and disul¢ram (see [3] for
references). In addition, CYP2A6 catalyses the C-oxidation of
nicotine to cotinine [4^6], the major metabolic pathway of
nicotine, and also carries out the subsequent 3P-hydroxylation
of cotinine [7]. Pianezza and coworkers [8] have presented
results indicating that inter-individual variability in the
CYP2A6 activity a¡ected smoking behaviour. They presented
results indicating that a lower number of subjects carrying
defective CYP2A6 alleles were found in a tobacco-dependent
group as compared to a never tobacco-dependent group and
that smokers carrying a defective CYP2A6 allele smoked few-
er cigarettes. Thus, these results could implicate that carriers
of defective CYP2A6 alleles would be at a lower risk of be-
coming smokers and thereby be protected from lung cancer
and other tobacco-related diseases.
Phenotyping with the probe drug coumarin has revealed a
pronounced inter-individual variability in the CYP2A6 activ-
ity [9^11]. In Caucasian populations, the prevalence of the
poor metaboliser (PM) phenotype for CYP2A6 appears to
be very low and there are only a few cases reported where
individuals completely lacked CYP2A6 activity [3,12]. By con-
trast, the frequency of PMs for CYP2A6 among Japanese
seems to be higher and in vitro studies using microsomes
from Japanese subjects demonstrated that eight out of 30
livers had a very low or no CYP2A6 immunoreactivity and
activity [13].
The CYP2A6 gene has been mapped to chromosome 19
between 19q12 and 19q13.2 [14]. It is located within a 350
kb gene cluster together with the CYP2A7 and CYP2A13
genes, two CYP2A7 pseudogenes as well as genes in the
CYP2B and CYP2F subfamilies [15]. Several variants of the
CYP2A6 gene have been described thus far. The CYP2A6*21
allele encodes an enzyme with a L160H substitution that does
not incorporate heme and is therefore inactive [17]. The orig-
inal PCR-based method for the detection of this allele [18] has
been found to occasionally yield erroneous results. Because of
this, we recently developed an improved a genotyping method
for the CYP2A6*2 allele [3], which avoids misclassifying in-
dividuals as PMs. Using this method, we determined a
CYP2A6*2 allele frequency of 1^3% in Caucasians popula-
tions in contrast to the 4^17% as otherwise reported [18,19].
In addition to the CYP2A6*2 allele, CYP2A6*3, proposed to
have been generated through a gene conversion between
CYP2A6 and the CYP2A7 pseudogene, was also suggested
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to be inactive [18]. Nunoya and coworkers have also brie£y
described an allele found in Japanese individuals where a part
of the CYP2A6 gene was deleted [20]. As expected, individuals
homozygous for this allele completely lacked both CYP2A6
mRNA and protein and were therefore CYP2A6 PMs.
Due to the important role that CYP2A6 has in the nicotine
metabolism and the recent report of a deleted CYP2A6 allele
[20], we considered it of interest to investigate the occurrence
of defective CYP2A6 alleles and the CYP2A locus in an ori-
ental population. To this end, we have characterised a CYP2A
locus which lacks the CYP2A6 gene, developed a rapid PCR-
based method for its detection and determined the frequency
of this allele in three di¡erent ethnic groups.
2. Material and methods
2.1. Subjects
Three di¡erent populations of Chinese, Spanish and Finnish origins
were used. Genomic DNA was obtained from 96 Chinese individuals
and 100 volunteers from the Zaragoza area in northern Spain, which
have been used earlier in CYP2D6 genotype-phenotype correlation
studies [21,22]. The Finnish population consisted of a random sample
of 100 healthy Finns (27^67 years old) living in the southwestern area
of Finland. We also genotyped DNA from 11 Thai individuals that
were previously phenotyped with coumarin [23]. This study was ap-
proved by the ethical committees at Karolinska Institutet and the
University of Oulu.
2.2. Southern blot analysis
Approximately 4 Wg of genomic DNA was digested with the restric-
tion endonuclease EcoRI and was subjected to electrophoresis for
3 days at 0.85 V/cm using a 0.8% agarose gel. Southern blot was
performed using Qiabrane positively charged nylon membranes
(Qiagen GmbH, Hilden, Germany). A 32P-labelled CYP2A6 probe
ranging from exon 6 to exon 9 was used to avoid hybridisation
with the CYP2A7PT and CYP2A7PC pseudogenes [18]. Densito-
metric analysis of the Southern blot fragments was performed using
a personal densitometer (Molecular Dynamics, Sunnyvale, CA, USA).
2.3. Long PCR and DNA sequencing
A GeneAmp XL PCR Kit (Perkin-Elmer, Norwalk, CT, USA) was
used to amplify the CYP2A7/CYP2A6 hybrid from genomic DNA of
individual Ch98 using the CYP2A7-speci¢c primer 5P-GCA CGT
TGA ACC TCT TCA TTG CA-3P located in exon 6 and the
CYP2A6-speci¢c primer 2A6R1 (see Table 1). The PCR fragments
and cosmids 19296 and 19019, containing the CYP2A6 and
CYP2A7 genes, respectively (kindly supplied by Dr. Linda K. Ash-
worth, LLNL Human Genome Center, Livermore, CA, USA) [15],
were partially sequenced on both strands with the ABI PRISM Big-
Dye terminator cycle sequencing kit and analysed on an ABI Prism
377 DNA sequencer.
2.4. CYP2A6 genotyping
Genotyping for the CYP2A6*2 allele was carried out essentially as
previously described [3]. The L-globin primers 5P-GAA GAG CCA
AGG ACA GGT AC-3P and 5P-TAG CCA CAC CAG CCA CCA
CT-3P were, however, also added to the reaction mixture at a ¢nal
concentration of 0.12 WM in order to amplify a part of the L-globin
gene as a positive control for the PCR reaction.
A two step PCR method was used to detect the CYP2A6del allele.
In the ¢rst PCR reaction (PCR I), a region from exon 7 to approx-
imately 420 bp downstream of exon 9 of CYP2A6 or the CYP2A7/
CYP2A6 hybrid was speci¢cally ampli¢ed. This PCR product was
subsequently used as a template in the second allele-speci¢c PCR
reaction (PCR II). PCR I was done using the primers 2Aex7F and
2A6R1 (see Table 1). The reaction mixture contained approximately
50 ng genomic DNA, 0.25 WM of each primer, 0.2 mM of each dNTP,
1.2 mM MgCl2, 0.6 U of Taq polymerase (Advanced Biotechnologies,
Epsom, UK) and was carried out in 1UReaction Bu¡er IV (Ad-
vanced Biotechnologies) in a total volume of 25 Wl using a Perkin
Elmer GeneAmp PCR System 2400 or 9700. The initial denaturation
was performed at 95‡C for 1 min, followed by 35 cycles each consist-
ing of denaturation at 95‡C for 15 s, annealing at 60‡C for 20 s and
extension at 72‡C for 3 min, followed by a ¢nal extension at 72‡C for
7 min.
The mixture for the allele-speci¢c reaction (PCR II) contained 0.8
Wl PCR I product, 0.25 WM of primer 2A6ex8F or primer 2A7ex8F,
0.25 WM of primer 2A6R2 (see Table 1), 0.1 mM of each dNTP, 1.0
mM MgCl2, 0.3 U of Taq polymerase and was done in bu¡er con-
sisting of 10 mM Tris-HCl, pH 8.3 and 50 mM KCl in a total volume
of 25 Wl. The ampli¢cation was performed by initial denaturation at
95‡C for 1 min, followed by 14 cycles each involving denaturation at
95‡C for 15 s, annealing at 52‡C for 20 s and extension at 72‡C for
2 min. 8 Wl of the PCR products was subsequently analysed on a 1.0%
agarose gel (Life Technologies, Rockville, MD, USA) stained with
ethidium bromide.
3. Results
3.1. The allele frequency of the CYP2A6*2 allele in a Chinese
and a Finnish population
We used our previously described method [3] to genotype
the CYP2A6*2 allele on a population of 96 Chinese individ-
uals. In three of the samples, we failed to obtain any ampli-
¢cation product with our CYP2A6-speci¢c primers located in
exon 1 and exon 4, although the L-globin fragment was am-
pli¢ed in all cases (data not shown). This suggested that these
subjects were homozygous for an allele lacking the CYP2A6
gene, therefore these samples were analysed further in greater
detail (see below). The other 93 samples were subjected to the
allele-speci¢c second PCR reaction. No CYP2A6*2 alleles
were, however, detected in the Chinese population. Similar
analysis of genomic DNA from 100 Finns revealed a
CYP2A6*2 allele frequency of 3.0%, in accordance with our
previous results [3].
3.2. The structure of the CYP2A locus in individuals with a
deleted CYP2A6 gene
The CYP2A locus has previously been mapped with the
restriction endonuclease EcoRI [15]. We therefore carried
out a Southern blot analysis using EcoRI on genomic DNA
from 15 Chinese individuals, including one of the individuals
in which the CYP2A6 gene could not be ampli¢ed (Ch98).
Southern blot analysis of cosmids from the CYP2A locus
revealed that in a normal CYP2A locus, the 6.6 kb, 7.5 kb
and 7.7 kb fragments correspond to the CYP2A6, CYP2A7
and CYP2A13 genes, respectively. The faint 15 kb fragment
likely represents another part of the CYP2A13 gene or anoth-
er related sequence.
Interestingly, individual Ch98 completely lacked the 7.5 kb
fragment (Fig. 1A). Our explanation for the Southern blot
pattern is that this subject carried two alleles with CYP2A6
gene deletions. An unequal crossover event which has oc-
curred between the 3P-£anking regions of the CYP2A6 and
CYP2A7 genes would lead to the loss of both the 7.5 kb
and 6.6 kb fragments and generate a novel CYP2A7/
CYP2A6 hybrid fragment of 6.6 kb (Fig. 1B). Densitometric
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Table 1
Primers used to genotype for the CYP2A6del allele
Primer Sequence
2Aex7F 5P-GRC CAA CAT GCC CTA CAT G-3P
2A6ex8F 5P-CAC TTC CTG AAT GAG-3P
2A7ex8F 5P-CAT TTC CTG GAT GAC-3P
2A6R1 5P-GCA CTT ATG TTT TGT GAG ACA TCA GAG ACA A-3P
2A6R2 5P-AAA ATG GGC ATG AAC GCC C-3P
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quanti¢cation of the relative intensity of the 7.5 kb fragment
from 15 di¡erent individuals divided them into three distinct
groups, which corresponded to having either 0, 1 or 2 copies
of the CYP2A6 gene (see Table 2).
In order to design gene-speci¢c primers in the 3P-£anking
regions of the CYP2A6 and CYP2A7 genes, we sequenced 520
bp downstream of exon 9 using the cosmids which contain
either the CYP2A6 or CYP2A7 gene. As expected, the sequen-
ces were very similar but a number of regions with di¡erences
were found (see Fig. 2). The CYP2A6-speci¢c primer 2A6R1,
which was designed in one of these regions, was used together
with a CYP2A7-speci¢c primer in exon 6 to amplify the
CYP2A7/CYP2A6 hybrid from individual Ch98. The PCR
fragment was partially sequenced and this showed that the
proximal 3P £ank consisted of the CYP2A7 sequence, whereas
the region further downstream had the CYP2A6 sequence
(Fig. 2). Thus, the breakpoint for the unequal crossover is
likely situated in the 82 bp region of the identical sequence,
de¢ned as the ‘deletion junction region’.
3.3. PCR-based detection of the deleted CYP2A6 gene
In order to facilitate genotyping for the CYP2A6del allele,
we developed a PCR-based method as outlined in Fig. 3A. In
the ¢rst PCR reaction (PCR I), a fragment extending from
exon 7 to 420 bp downstream of exon 9 was ampli¢ed in both
the CYP2A6*1 and CYP2A6del alleles. This reaction yielded a
1.9 kb product from all individuals and therefore also acts as
a positive control for the PCR reaction. This fragment was
subsequently used as a template for an allele-speci¢c PCR
method (PCR II). In this reaction, primers were speci¢cally
designed for ampli¢cation of either the CYP2A6*1 or the
CYP2A7/CYP2A6 hybrid found in individuals with the CY-
P2A6del allele, allowing for the convenient detection of het-
erozygous or homozygous carriers of the CYP2A6del allele
(see Fig. 3). Because the 3P-£anking region from +40 to
+120 is polymorphic in certain individuals ([3], M. Oscarson,
unpublished observations), we opted to amplify a relatively
long fragment to avoid using primers in this region. As shown
in Table 2, our PCR method could correctly predict the geno-
type of all 15 individuals which were analysed by a Southern
blot.
3.4. Correlation between genotype and phenotype
The PCR-based genotyping method was validated with re-
spect to the in vivo CYP2A6 activity by genotyping 11 Thai
individuals who had previously been phenotyped with cou-
marin [23]. One individual, that completely lacked CYP2A6
activity in vivo, was found to be homozygous for the CY-
P2A6del allele and two individuals, who excreted only 1.2
and 3.7 mg of 7-OH-coumarin, respectively, were heterozy-
gous for the CYP2A6del allele. The other eight individuals
were homozygous for the CYP2A6*1 allele and excreted on
average 5.6 mg 7-OH-coumarin (range 1.0^11.9). Thus, the
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Table 2
Correlation between the CYP2A6 genotype determined by a South-
ern blot and by the allele-speci¢c PCR method
Individual Relative intensity Genotype determined by PCR
(7.5 kb band/7.7 kb
band)a
Ch72 1.5 *1/*1
Ch73 1.5 *1/*1
Ch78 0.5 *1/del
Ch79 1.3 *1/*1
Ch81 0.5 *1/del
Ch84 0.4 *1/del
Ch85 1.4 *1/*1
Ch92 0.5 *1/del
Ch93 1.3 *1/*1
Ch94 1.3 *1/*1
Ch95 0.5 *1/del
Ch96 1.6 *1/*1
Ch97 0.5 *1/del
Ch98 0.0 del/del
Ch99 1.4 *1/*1
aThe constant 7.7 kb fragment was used as an internal standard for
DNA loading.
Fig. 1. A: Southern blot analysis of the CYP2A genes in genomic DNA from Chinese individuals using the restriction endonuclease EcoRI.
MW, 1 kb plus DNA ladder (Life Technologies, Rockville, MD, USA). B: The proposed mechanism for the CYP2A6 gene deletion which was
generated through an unequal crossover event. The outcome would be the CYP2A6del allele and a hypothetical allele containing two CYP2A6
genes in tandem. EcoRI restriction sites are shown with vertical lines. Fragment lengths generated by EcoRI digestion were previously deter-
mined by cosmid mapping [15]. Genes are represented by black boxes and the start codons are indicated by bent arrows.
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presence of the CYP2A6del allele correlated well with the
observed in vivo coumarin-7-hydroxylase activity.
3.5. Allele frequencies of the CYP2A6del allele
To estimate the frequency of the CYP2A6del allele, we gen-
otyped almost 300 subjects belonging to three di¡erent ethnic
groups, namely 96 Chinese individuals, 100 Finns and 100
individuals from northern Spain. In the Chinese population,
we observed an allele frequency of 15.1% (Table 3). Three of
the 96 individuals were homozygous for the CYP2A6del allele,
indicative of a PM phenotype. The CYP2A6del allele was,
however, rare in the two Caucasian populations and only
three individuals in total were heterozygous for the CYP2A6-
del allele.
4. Discussion
In the present study, we have characterised a CYP2A locus
completely lacking the CYP2A6 gene using a sequence anal-
ysis of cosmids, gene fragment analysis by Southern blot and
PCR ampli¢cation. We have also developed a reliable PCR
method for the rapid screening of the CYP2A6 gene deletion,
which accurately predicts the CYP2A6 phenotype. The gene
deletion is most likely similar or identical to one of the defec-
tive alleles recently described by Kamataki and collaborators
[20,24] but the limited amount of data presented by these
authors did not allow for a detailed comparison to be made.
A striking inter-ethnic di¡erence in the distribution of the
CYP2A6del allele was found as a high frequency was observed
in the Chinese population, in contrast to the very low fre-
quency seen in Caucasians. This indicates that the CYP2A6
deletion is a relatively recent genetic event which occurred
after the Caucasoid/Asian split 35 000 years ago [25]. In con-
trast, the CYP2D6 gene deletion which creates the CYP2D6*5
allele, appears to be a much older genetic event because the
frequency of CYP2D6*5 is between 2 and 5% in all popula-
tions studied [26].
We propose that the CYP2A6del allele was generated
through an unequal crossover event between non-allelic se-
quences involving an unequal pairing of homologous chromo-
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Table 3
CYP2A6 genotypes and allele frequencies in Chinese, Finnish and Spanish populations determined by allele-speci¢c PCR methods
Population Genotypes frequency (%) Alleles frequency (%)
*1/*1 *1/*2 *2/*2 *1/del *2/del del/del CYP2A6*1 CYP2A6*2 CYP2A6del
Chinese (n = 96) 72.9 0.0 0.0 24.0 0.0 3.1 84.9 0.0 15.1
Finns (n = 100) 92.0 6.0 0.0 2.0 0.0 0.0 96.0 3.0 1.0
Spaniards (n = 100) 93.0 6.0a 0.0a 1.0 0.0 0.0 96.5 3.0a 0.5
aData are from Oscarson et al. [3].
Fig. 2. The DNA sequence of the 3P-£anking region of the CYP2A6 and CYP2A7 genes and the CYP2A6del allele. The light gray shaded
boxes represent di¡erences between the CYP2A sequences. The proposed crossover region, in which the CYP2A6 and CYP2A7 sequences are
identical, is indicated by the black box. Arrows above the sequences indicate the CYP2A6-speci¢c reverse primers used for genotyping. Num-
bering of the sequence begins with the ¢rst base pair following the stop codon (underlined).
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somes or sister chromatids. Our sequence analysis revealed
that the deletion junction region of 82 bp is located approx-
imately +150 bp from the CYP2A6 gene. This region has also
recently been proposed by Yokoi and Kamataki [24] to be a
breakpoint region. A similar mechanism for gene deletion is
involved in the generation of alleles lacking either the
CYP2D6 or GSTM1 genes [27,28]. The other outcome of an
unequal crossover event is an insertion creating an allele with
two active genes in tandem, causing more enzyme to be ex-
pressed and thereby an increased enzyme activity. Indeed, in-
dividuals have been found where either the CYP2D6 or the
GSTM1 gene is duplicated [29,30] and it is likely that subjects
also carrying alleles with duplicated CYP2A6 genes exist.
Such alleles could, however, have been eliminated through
an evolutionary pressure.
Our novel genotyping method for the CYP2A6*2 allele [3]
was also used on the Chinese population studied. Interest-
ingly, we did not detect any CYP2A6*2 alleles in the Chinese
population, in contrast to the 11^20% previously reported
[18]. One possible explanation for this di¡erence could be
that individuals were misclassi¢ed in the earlier studies due
to the erroneous method used.
The results presented by Pianezza and coworkers [8] indi-
cate a relationship between the distribution of defective
CYP2A6 alleles and the likelihood for an individual to be-
come a smoker as well as the number of cigarettes smoked
per day. Thus, CYP2A6 PMs would be at a lower risk of
becoming smokers and thereby be protected from lung cancer
and other tobacco-related diseases. Many pre-carcinogens
found in tobacco smoke are also activated by CYP2A6 [1]
and it could be speculated that PMs would activate these
pre-carcinogens at a reduced rate, thereby gaining an addi-
tional protective e¡ect against tobacco smoke. This could be
of particular importance in the oriental populations where the
frequencies of PMs and heterozygotes are considerably higher
than in Caucasians. The genotyping method presented herein
will facilitate molecular epidemiological studies aimed at elu-
cidating the potential impact of the CYP2A6 genotype on
such diseases.
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